LT16 outperformed existing antiandrogens by fully antagonizing clinical AR mutations and effectively suppressing castration- and enzalutamide-resistant LNCaP cells proliferation in vitro and in vivo, positioning it as a promising and innovative therapeutic for advanced PCa.
Xin Chai, Xinyue Wang, Lvtao Cai et al.· Journal of Medicinal Chemist...· 2 citations
Resistance-conferring mutations in the androgen receptor (AR) ligand-binding pocket (LBP) compromise the effectiveness of clinically approved orthosteric AR antagonists. Targeting the dimerization interface pocket (DIP) of AR presents a promising therapeutic approach. In this study, we report the design and optimizatio...
Jin-Biao Liao, J. Liao, Yanzhen Yu et al.· Journal of Medicinal Chemist...· 1 citation
This work proposes a novel strategy that incorporates two models: a fragment-based model (Frag-MD) and a character-based model (MD), both integrating a conditional transformer, recurrent neural networks, and reinforcement learning that holds the potential to establish a new paradigm for discovering novel PSs applicable...
Kepeng Chen, Xiaoting Zhang, Ji-Ke Wang et al.· Chemical Science· 4 citations
Advances in elucidating the molecular mechanisms underlying AR conformational regulation are summarized and progress in the structure-based design and development of novel AR antagonists are highlighted, highlighting the power of computation-driven approaches in drug discovery.
Xin Chai, Tingjun Hou, Dan Li· Accounts of Chemical Researc...· 0 citations
Accurate prediction of metalloprotein-ligand interactions is critical for metalloprotein-targeted drug discovery. Conventional docking tools and existing deep learning (DL) models fail to reliably capture metal-ligand interactions, hampering the discovery of potent metalloprotein inhibitors. Here, we propose MetalloDoc...
Hui Zhang, Xujun Zhang, Qun Su et al.· Journal of the American Chem...· 6 citations
D8, which contained 2-oxo-tetrahydroquinoline by carbonyl migration form B53, manifests an excellent SGRM with remarkable transrepression potency and optimized binding mode within the GR LBD, underscoring its therapeutic potential and validating the design strategy.
Xiaodong Bao, Yuxin Zhou, Zhaoxu Yang et al.· Journal of Medicinal Chemist...· 1 citation
The AI-guided development of a first-in-class proteolysis-targeting chimera (PROTAC) designed to selectively degrade the CLIP1-LTK fusion protein is reported, providing a promising therapeutic strategy for overcoming acquired resistance in kinase-driven cancers.
Shi-Cheng Chen, Hai-Ting Duan, S. Zhong et al.· Proceedings of the National...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.